This report, for the first time, demonstrates high efficacy of novel CS1-CAR-T cells and CS1-BCMA CAR-T cells in targeting multiple myeloma and provides a basis for future clinical studies. This evidence concerns the gene SLAMF7 and plasma cell myeloma.